Daily Papers

Diffusion language models, as a promising alternative to traditional autoregressive (AR) models, enable faster generation and richer conditioning on bidirectional context. However, they suffer from a key discrepancy between training and inference: during inference, MDLMs progressively reveal the structure of the generated sequence by producing fewer and fewer masked tokens, whereas this structure is ignored in training as tokens are masked at random. Although this discrepancy between training and inference can lead to suboptimal performance, it has been largely overlooked by previous works, leaving closing this gap between the two stages an open problem. To address this, we frame the problem of learning effective denoising trajectories as a sequential decision-making problem and use the resulting framework to apply reinforcement learning. We propose a novel Masked Diffusion Policy Optimization (MDPO) to exploit the Markov property diffusion possesses and explicitly train the model under the same progressive refining schedule used at inference. MDPO matches the performance of the previous state-of-the-art (SOTA) method with 60x fewer gradient updates, while achieving average improvements of 9.6% on MATH500 and 54.2% on Countdown over SOTA when trained within the same number of weight updates. Additionally, we improve the remasking strategy of MDLMs as a plug-in inference replacement to overcome the limitation that the model cannot refine tokens flexibly. This simple yet effective training-free strategy, what we refer to as RCR, consistently improves performance and yields additional gains when combined with MDPO. Our findings establish great potential for investigating the discrepancy between pre-training and inference of MDLMs. Code: https://github.com/autonomousvision/mdpo. Project Page: https://cli212.github.io/MDPO/.

Drug discovery is a complex process that involves multiple scenarios and stages, such as fragment-constrained molecule generation, hit generation and lead optimization. However, existing molecular generative models can only tackle one or two of these scenarios and lack the flexibility to address various aspects of the drug discovery pipeline. In this paper, we present Generalist Molecular generative model (GenMol), a versatile framework that addresses these limitations by applying discrete diffusion to the Sequential Attachment-based Fragment Embedding (SAFE) molecular representation. GenMol generates SAFE sequences through non-autoregressive bidirectional parallel decoding, thereby allowing utilization of a molecular context that does not rely on the specific token ordering and enhanced computational efficiency. Moreover, under the discrete diffusion framework, we introduce fragment remasking, a strategy that optimizes molecules by replacing fragments with masked tokens and regenerating them, enabling effective exploration of chemical space. GenMol significantly outperforms the previous GPT-based model trained on SAFE representations in de novo generation and fragment-constrained generation, and achieves state-of-the-art performance in goal-directed hit generation and lead optimization. These experimental results demonstrate that GenMol can tackle a wide range of drug discovery tasks, providing a unified and versatile approach for molecular design.